Since 2008 the Royal Society Enterprise Fund has invested in a portfolio of five companies.

Sphere Fluidics Professor Wilhelm Huck, Professor Chris Abell and Dr Frank Craig of Sphere Fluidics. Image copyright: Cambridge Enterprise.
  • OrganOx: has developed a process which allows donated livers to be preserved for longer periods during storage and transportation, thereby significantly increasing the supply of organs for life-saving transplant operations.
  • Base4Innovation: is developing a radically new method of ultra-fast DNA sequencing using techniques based on silicon chip technology.
  • N-PSL: is manufacturing novel and compact filtration technology that improves energy consumption in a wide range of industrial applications, including compressed air treatment.
  • Sphere Fluidics: is developing miniature droplet technology that enables ultra-rapid chemical analysis of cells and molecules, applicable to a wide range of markets including drug development, biocatalysts and algal biofuels.

The Royal Society
Enterprise Fund

A new initiative aimed at providing equity finance and other support to start up companies with outstanding potential founded on excellent science and technology. Read more about the Royal Society Enterprise Fund.


The Royal Society Enterprise Fund welcomes proposals for syndicated investments in partnership with other individuals and organisations.

To make a proposal please contact us.

  • Online: Send a message to us
  • Email: enterprisefund@royalsociety.org
  • Write to: The Royal Society Enterprise Fund,
    The Royal Society, 6-9 Carlton House Terrace, London SW1Y 5AG